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Objectives:Theaimof thisstudy istodescribeand illustratea methodto obtain early estimatesof theeffectivenessof anewversionof a medicaldevice.
Methods:In the absenceof empiricaldata, expertopinionmay be elicitedontheexpected differencebetweenthe conventionaland modiﬁeddevices.BayesianMixedTreatment Comparison(MTC)
meta-analysiscan thenbe usedto combinethisexpert opinionwithexistingtrialdata onearlierversionsof thedevice.Weillustratethisapproach for anewfour-pole implantablecardioverter
deﬁbrillator(ICD) compared withconventionalICDs, ClassIII anti-arrhythmicdrugs, and conventional drug therapy for thepreventionof sudden cardiacdeath inhighriskpatients. ExistingRCTswere
identiﬁedfroma publishedsystematicreview,and weelicitedopiniononthe differencebetweenfour-poleand conventionalICDs fromexpertsrecruitedat a cardiologyconference.
Results:Twelverandomized controlledtrialswereidentiﬁed.Sevenexpertsprovided validprobability distributions forthe newICDscompared withcurrentdevices.TheMTC modelresultedin
estimated relativerisksofmortality of 0.74 (0.60–0.89) (predictiverelativerisk[RR]= 0.77 [0.41–1.26]) and 0.83 (0.70–0.97) (predictive RR=0.84 [0.55–1.22])withthe newICD
therapy comparedto ClassIII anti-arrhythmicdrug therapy and conventionaldrug therapy, respectively.Theseresultsshowednegligibledifferencesfromthe preliminaryresultsfor theexistingICDs.
Conclusions: Theproposed method incorporatingexpertopiniontoadjust fora modiﬁcationmadeto an existingdevicemay play a useful roleinassistingdecisionmakersto makeearly informed
judgmentson theeffectivenessoffrequently modiﬁedhealthcaretechnologies.
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Medical devices differ from pharmaceuticals in terms of the
nature and quantity of evidence about their effectiveness and
cost-effectiveness. The medical device industry is a dynamic
sector where new technologies are continuously developed, and
the life cycle of a particular version of a device is often less
than 2 years. Frequent technological improvements are made
without changing major features or functionality. With such
rapidincrementalchange,itcanbedifﬁculttokeeptheevidence
up-to-date.
The regulatory environment for devices also differs from
that for pharmaceuticals. Evidence required for marketing ap-
proval may only describe technical performance rather than
clinical safety or efﬁcacy, let alone effectiveness or cost-
effectiveness. In the United States, new products can obtain
access to the market without being tested on patients if they are
considered “substantially equivalent” to previously approved
devices. Among numerous examples is the artiﬁcial hip known
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asthearticularsurfacereplacementfromDePuy,whichhasnow
been recalled due to the unusually high rate of implant failure.
The U.S. Food and Drug Administration has recently ap-
provedtheuseofanimplantablecardioverterdeﬁbrillator(ICD)
with four-pole (IS-4) lead connectors without premarket clini-
caltesting,andinsteadrequiredapost-approvalstudy.Although
the new IS-4 device is said to confer beneﬁts such as a smaller,
lower-proﬁle pulse generator, there have been some concerns
that such a modiﬁcation should be clinically tested before ap-
proval (10).
This leaves potential early adopters—clinicians, patients,
and payers—with a difﬁcult decision. Unless a new version of
a medical device is a genuine breakthrough, its effects will be
largely predictable from information on previous generations.
Butthisdoesrequireajudgmentonwhetherdemonstratedtech-
nicalimprovementsarelikelytotranslateintoclinicalgains,and
if so, whether these are sufﬁcient to justify the (usually higher)
cost. Furthermore, potential users have to judge the likelihood
of unforeseen adverse effects.
Theaimofthisstudyistodevelopamethodtohelpdecision
makers make an informed, early assessment of a new version
of a medical device. We suggest that Bayesian bias-adjustment
techniques may be adapted to combine existing information on
earlier generations of the device with expert judgments about
the extent to which the new version is likely to differ. In the
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following section, we explain the method in more detail. We
then illustrate the method using the example of four-pole ICDs.
The advantages and disadvantages of this approach are then
discussed.
METHODS FOR EARLY EVALUATION OF A MODIFIED TECHNOLOGY
The Bayesian approach resembles the human cognitive proce-
dure of acquiring knowledge by updating a prior understanding
as new information becomes available. Usually, the prior view
is supported by scant or poor-quality data, or it may even be
based on subjective opinion alone. As more or better empirical
evidence emerges, priors are updated to derive posterior esti-
mates.Insuchcases,thereisusuallylessuncertaintyaroundthe
posterior, than around the prior state of knowledge. We propose
to adapt this method for the situation where there is a strong
body of evidence on an existing technology, and only weak
evidence or beliefs about how a new modiﬁed version of the
technology differs. Here, posterior estimates of the effective-
ness of the modiﬁed technology will be less certain than the
prior knowledge about earlier generations of the device.
Bayesianmethodsofmeta-analysispoolevidencefromclin-
ical trials to estimate the effectiveness of health technologies.
The meta-analysis requires assumptions about the heterogene-
ity of treatment effects: a ﬁxed effect model assumes a common
true effect underlying all study results, whereas a random ef-
fects model assumes that trials draw a random sample from
the distribution of true effects. The standard pair-wise meta-
analysis can be extended to a Mixed Treatment Comparison
(MTC) meta-analysis when exploring the relative efﬁcacy of a
range of interventions (2). This integrates information from a
network of direct and indirect comparative trials within a single
model (12). This does, of course, require assumptions about the
consistency of the underlying evidence. Bayesian computation
is possible with Monte Carlo Markov chain (MCMC) methods
using WinBUGS, a freely available statistical software package
(16).
These Bayesian meta-analysis techniques may be extended
to adjust for suspected “biases” in the evidence base. For ex-
ample, Welton and colleagues (25) included additive bias pa-
rameters to adjust the results of studies that lacked appropriate
allocation concealment, estimating the extent of this bias from
a large meta-epidemiological study. And Turner et al. (23) in-
corporated a wide range of possible biases, from selection bias
to health outcome bias, using expert judgment to identify and
quantify them.
We borrow this idea, introducing an adjustment parameter
to reﬂect beliefs about the difference in effectiveness between
a new and an existing version of a device. This can be added to
an estimate of treatment effect from a random-effects Bayesian
MTC meta-analysis of trial evidence for the existing device,
to obtain an estimate of effectiveness for the new device (see
Appendix 1 for a more formal mathematical description of this
idea). This relies on the assumption that the new device is
sufﬁciently similar to the existing one, and that its effect is
predictable from data on the earlier version. And, of course,
the same assumptions about the consistency between direct and
indirect evidence for the existing device must still hold, as for
any MTC analysis.
The probability distribution for the difference parameter,
denoted as β, can be estimated from expert opinion. There are
many ways in which such distributions can be elicited to reﬂect
individuals’ degrees of belief and extent of uncertainty over the
location of an unknown parameter. In our example below, we
elicited this information in the form of histograms, with experts
asked to state the probability of the parameter lying within each
of a series of ﬁnite intervals.
There are also many ways in which individuals’ subjective
probability estimates can be pooled. In our example, we com-
bined histograms from several experts by dividing the intervals
on which opinion was elicited to obtain the smallest subinter-
vals, and taking the arithmetic means of the probabilities for
each of the subintervals across the experts. To illustrate, sup-
pose that Expert 1 said there was a 50 percent probability that
theparameterlayineachoftwointervals:(0,1)and(1,2).Expert
2saidtherewasa50percentprobabilitythatitlayineachofthe
intervals (0,1) and (1,3). Then, one might say that the elicited
probabilities for three subintervals, (0,1), (1,2) and (2,3), are 50
percent, 37.5 percent, and 12.5 percent, respectively.
Appropriate scale conversion (Appendix 1) provides a
pooled discrete probability distribution for β, which can be
usedtodirectlysamplevaluesforthisparameterintheBayesian
MCMC model. Alternatively, one might ﬁt a suitable paramet-
ric distribution to reﬂect the pooled opinion. In our example
reported below, we found that the elicited distribution was ap-
proximately normal, so we calculated the mean of β from the
discrete distribution, and used a variation on a univariate least
squares ﬁtting method (19) to ﬁnd its standard deviation. Sam-
ples from the ﬁtted Normal distribution for β were then incor-
porated into the main MTC model.
Inothercircumstances,otherparametricdistributionsmight
provide a better ﬁt for the elicited data: for a more complete
discussion of distribution selection, see O’Hagan et al. (19).
ILLUSTRATIVE EXAMPLE: ICDS
The Review Question
Our example concerns the use of ICDs in the prevention of sud-
dencardiacdeathinhighriskpatientswithalowleftventricular
ejection fraction (LVEF < 35–40 percent). These patients often
have a history of myocardial infarction and/or congestive heart
failure. We included interventions targeted at individuals who
have not yet experienced a major arrhythmic event (primary
prevention), and those targeted at people who have survived
such an event (secondary prevention) (9).
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Figure 1. Illustration ofanalyticalapproach.
We distinguish four broad types of Treatment: (A) Conven-
tional drug therapy (which may include beta-blockers or ACE
inhibitors); (B) Conventional drug therapy and Class III Anti-
arrhythmic drug therapy (such as amiodarone or sotalol); (C)
Conventional drug therapy and conventional ICD therapy; and
(D) Conventional drug therapy and four-pole connector ICD
therapy.
“Conventional” drug therapy was deﬁned to include any
drugs other than class III anti-arrhythmics, provided they are
also prescribed for patients in the other arms of the trial. Inter-
ventions might also include other surgical procedures such as
coronary artery bypass graft, provided these were also common
“underlying” treatments across all arms within the same RCT.
All four interventions can be used in primary or secondary
prevention, although conventional drug therapy alone is rela-
tively unusual in secondary prevention.
Review of Evidence on Current ICDs
Clinical trial data on existing ICDs was obtained from a
recently-published systematic review by Ezekowitz and col-
leagues (9). They report details about the search strategy, the
characteristics of the included studies and the extent of hetero-
geneity. Although this review included both randomized and
observational studies, we focused only on RCT data for illus-
trative purposes.
Twoauthors(J.Y.andK.H.)extracteddatafromtheoriginal
papers cited in the Ezekowitz review, and also checked other
papers related to each trial if information given in the cited ones
was insufﬁcient.
Meta-analysis Model
We used a Bayesian MTC meta-analysis to estimate the rela-
tive risk of death for patients under the existing ICD therapy
(treatment C) compared with non-ICD therapies (treatments A
and B). A hierarchical random effects model was used, assum-
ing study-level treatment effects to be a random sample drawn
from a probability distribution for the overall treatment effect
governed by a set of common parameters. The model assumes a
lognormal distribution for the relative risks, and applies diffuse
priors (this is a common MTC model) (12). Conventional drug
therapy (treatment A) was taken as the reference treatment for
the meta-analysis.
ThedistributionfortherelativeeffectivenessofthenewICD
(treatment D), for which there is not yet any RCT evidence,
is assumed to be the same as that for C, except its mean is
shifted by an adjustment parameter β, which is also assumed
to be normally distributed. The mean and variance of β was
estimated from elicited expert opinion.
The meta-analysis model and adjustment for the ICD ex-
ample is illustrated in Figure 1, and the BUGS code is provided
in Appendix 2.
Elicitation Method
Preliminary discussions with two practicing cardiologists led
us to focus on the practicality of our elicitation methods, so
we adopted a rather simpler approach than that advocated in
the literature (15). Our paper-based questionnaire was reﬁned
after these discussions, to focus and standardize the elicitation
process (see Appendix 3).
Data were collected through face-to-face interviews with
individuals recruited at a cardiology conference (after a ses-
sion devoted to discussion on advanced device treatments for
arrhythmias at the Heart Rhythm Congress 2009). This pro-
vided an opportunity to clarify the questions if required. Par-
ticipants were ﬁrst asked about their clinical expertise and
117 INTL. J. OFTECHNOLOGY ASSESSMENT IN HEALTH CARE 28:2, 2012Youn etal.
Treatment A  vs. Treatment C
SCD-HeFT(5)
DINAMIT  (12)
DEFINITE (14)
MADIT-II (19)
CABG-PATCH (6)
COMPANION (7)
CAT (4)
Pooled eﬀect (A vs. C)
0.0 0.5 1.0 1.5
AVID (22)
CIDS (8)
MADIT-I (18)
AMIOVIRT (21)
CASH (15)
Pooled eﬀect (B vs. C) 
Treatment B  vs. Treatment C
RR (mean, 95% CrI)
0.79 (0.67-0.91)
0.93 (0.74-1.24)
0.79 (0.58-1.00)
0.77 (0.62-0.92)
0.95 (0.77-1.22)
0.83 (0.68-1.00)
0.82 (0.59-1.12)
0.83 (0.70-0.97)
0.70 (0.56-0.86)
0.81 (0.66-1.00)
0.64 (0.41-0.85)
0.77 (0.51-1.09)
0.78 (0.61-1.01)
0.75 (0.59-0.90)
ICD 
(r/n)
182/829
62/332
28/229
105/742
101/446
105/595
13/50
244/847
58/342
40/229
97/490
95/454
131/617
17/54
Others 
(r/n)
80/507
83/328
15/95
6/51
36/99
122/509
98/331
39/101
7/52
40/92
0.84 (0.55-1.25) Predic ve eﬀect (A vs. C)
Predic ve eﬀect (A vs. D) 0.84 (0.55-1.22)
Predic ve eﬀect 
(B vs. C)
0.77 (0.42-1.29)
0.77 (0.41-1.26) Predic ve eﬀect 
(B vs. D) 
Vs. Treatment D
Vs. Treatment D
SCD-HeFT(5) 182/829 240/845 0.77 (0.66-0.89)
Figure2. MixedtreatmentcomparisonoftheconventionalICD(TreatmentC)andothertherapies(TreatmentsA&B),andthepredictednewICDeffect.TreatmentA:Conventionaldrugtherapy;TreatmentB:Anti-arrhythmic
drug therapy;TreatmentC: ConventionalICD therapy;TreatmentD: Four-poleconnectorICD therapy.Dashed lines:thepredictiveposteriorsestimated fromtheMTC modelwith and withoutadjustmentfor β.
familiarity with ICD implantation. They were then given some
simple summary information about the 5-year mortality rate
with “conventional” ICDs, based on the results of two, large
trials. The experts were then asked to estimate the most likely
value, and lower and upper limits, for the relative mortality rate
with the four-pole IS-4 ICD. Finally, they were asked to dis-
tribute 100 points along a line showing different numbers of
lives gained or lost with the four-pole device in comparison
with a “conventional” ICD to reﬂect their subjective beliefs.
The comparison against “conventional” ICD was intended to
simplify elicitation and analysis, although it does neglect possi-
bledifferencesbetweencurrentICDdevices.Weusedstatistical
tests of heterogeneity on the trial data to look for evidence of
such differences.
As the model estimates the logarithm of relative mortality,
elicited absolute mortality values were converted to an appro-
priate scale (see Appendix 1). Microsoft Excel and R software
tools were then used to calculate a combined discrete distribu-
tion for the difference-adjustment parameter, and to test and ﬁt
a normal distribution, as described above.
RESULTS
Literature Review
The systematic review by Ezekowitz and colleagues (9) iden-
tiﬁed twelve RCTs that reported all-cause deaths during the
follow-up period and the number of study participants for each
treatment arm (3–7;11;13;14;17;18;20;21).
Ezekowitz et al. made pair-wise comparisons between ICD
and non-ICD treatments. However, for our MTC analysis,
we further classiﬁed the non-ICD treatments as conventional
drug therapy alone (A) and conventional drug therapy com-
bined with a Class III Anti-arrhythmic drug therapy (B). One
study, the CASH trial (14), reported data on three random-
ized groups: (i) metoprolol (a beta blocker), (ii) amiodarone
(a Class III anti-arrhythmic), and (iii) conventional ICD. We
excluded the metoprolol arm, because this did not ﬁt our deﬁ-
nition of “conventional drug therapy” (treatment A), because
it was not also co-prescribed in the other treatment arms.
The ﬁnal list of data included in our analysis is shown in
Figure 2.
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Table 1. The Posterior Mean (95% Credible Interval) of Selected Relative Effectiveness Measures Regarding Mortality (τ2: Between-Study Variance,
i.e., HeterogeneityParameter)
ICDsvs.TreatmentB ICDsvs.TreatmentA
a)ExistingICDs(TreatmentC) Primary and secondary prevention trials combined (12 trials) (n =9266)
Log RR −0.30 Log RR −0.20
(−0.52,−0.11) (−0.36,−0.03)
RR 0.75 RR 0.83
(0.59,0.90) (0.70,0.97)
PredictiveRR 0.77 PredictiveRR 0.84
(0.42,1.29) (0.55,1.25)
τ2 =0.031, Posteriormean of residualdeviance=26.08
b) Four-poleconnectorICDs(TreatmentD) Primary and secondary prevention trials combined (12 trials)
with β adjustment(n = 9266)
Log RR −0.30 Log RR −0.19
(−0.52,−0.12) (−0.36,−0.03)
RR 0.74 RR 0.83
(0.60,0.89) (0.70,0.97)
PredictiveRR 0.77 PredictiveRR 0.84
(0.41,1.26) (0.55,1.22)
τ2 =0.031, Posteriormean of residualdeviance=26.55
Note. Treatment A: Conventional drug therapy; Treatment B: Anti-arrhythmic drug therapy; Treatment C: Conventional ICD therapy; Treatment D:
Four-poleconnectorICD therapy.
Primary versus Secondary Prevention
Ezekowitz et al. (9) reported similar estimates for the relative
risk of mortality in the primary prevention trials as in the sec-
ondary prevention trials. They noted that the extent of hetero-
geneity across all primary and secondary prevention trials was
moderate (I2 = 44.4 percent), although the primary prevention
trials showed an intrinsically wider variance.
We initially conducted separate Bayesian meta-analyses for
primary and secondary prevention trials to test whether they
are sufﬁciently homogeneous to be combined. For this analysis,
we excluded trials for which the control arm was Treatment A
because no secondary prevention trials included this treatment.
The results of this C-B comparison showed little difference be-
tween the estimated effects for primary prevention (relative risk
[RR]0.72(0.22–1.81),basedon3trials(4;17;20)N=1973)and
those for secondary prevention (RR 0.81 (0.41–1.46), based on
3trials(7;14;21),N=1866).(Notethatthedifferencesbetween
these results and those reported in (9) are due to differences in
the meta-analysis models (24), and in the data included – we
excluded three primary prevention trials with a Treatment A
control arm, and the metoprolol arm from the CASH study, as
mentioned above.)
Although this analysis suggested a relatively higher level
of heterogeneity between the primary prevention studies
(τ2 = 0.69) than between the secondary prevention studies (τ2
= 0.27), pooling all these trials resulted in a much lower level
of heterogeneity (τ2 = 0.03). This led us to conclude that the
use of ICD technology results in similar mortality beneﬁts in
primaryandsecondaryprevention,and,therefore,wecombined
these results.
Meta-analysis Results for Existing ICDs
Our main MTC model included 12 trials: nine primary preven-
tion trials (3–6;11;13;17;18;20) and three secondary prevention
trials (7;14;21).
The forest plot of treatment effects for all comparisons
involvingtheexistingICDtherapy(TreatmentC)andthepooled
estimates of mortality beneﬁts from the use of existing ICDs
are shown in Figure 2 and Table 1, respectively. Note that, in
Figure 2, the results for some studies (particularly DINAMIT,
CABG-PATCH, and MADIT-I) appear rather different to what
one might expect from the raw data, because of a “shrinkage
effect” (1). The relative risk estimate for the C-B comparison
(mean = 0.75 [95 percent CrI 0.59–0.90]) is lower than that for
the C-A comparison (mean = 0.83 [95 percent CrI 0.70–0.97]),
indicating a higher mortality risk associated with the Class III
anti-arrhythmicdrugtherapy(B)thanthatforconventionaldrug
therapy alone (A) (mean = 1.12 [95 percent CrI 0.89–1.42]).
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Figure 3. Combinedexperts’subjectivedistributions forthedifferencein mortality with thenewfour-poleICD comparedwith conventionalICD andtheﬁtted Normaldistribution.
(Similar ﬁndings were also reported in Tung et al. (22).) The
predictive posteriors for a future trial on conventional ICDs
show wider intervals: 0.77 (0.42–1.29) for the C-B comparison
and 0.84 (0.55–1.25) for the C-A comparison. Between-study
variability was moderate (τ2 = 0.031).
The model predictions were considered to offer adequate
goodness of ﬁt when the posterior mean residual deviance of
26.08 was compared to the number of data points, 25. For all
meta-analyses,standardchecksformodelconvergenceledtothe
use of 10,000 iterations as a burn-in, and the results presented
were obtained based on 20,000 iterations.
Elicitation of Expert Opinion
Seven experts provided valid probability distributions for the
mortalitydifferencewiththefour-poleICD.Wecannotcalculate
a response rate, as the invitation to participate was made in an
open conference session and two of the authors (K.H. and J.Y.)
approachedindividualsafterthesession.However,mostofthose
approached did agree to offer their opinion and complete the
elicitation form.
The mean and standard deviation of the ﬁtted distribution
for β were both close to zero, i.e., Normal (µβ = 0.0017,
σβ = 0.0060), reﬂecting expert opinion that the mortality im-
pactofthenewICDswouldbesimilartothatofcurrentdevices.
However, the positive mean value signiﬁes the belief that the
new device might slightly reduce mortality.
The pooled cumulative subjective probabilities from the
experts were compared against the cumulative density function
oftheNormaldistribution(Figure3).Althoughaweakdegreeof
skewness is observed in the empirical probability distribution,
the assumption that β follows a normal distribution appears to
be reasonable.
Adjusted Meta-analysis: Prediction for New ICD
The ﬁtted Normal distribution for β was incorporated into the
meta-analysistoestimatetheeffectivenessofthefour-polecon-
nector ICDs. The adjusted MTC results are provided in Table 1.
The estimates in Table 1 show extremely small differences
between the estimated mortality effects of the old and new
ICDs: RR of 0.75 (0.59–0.90) for C versus B and 0.74 (0.60–
0.89) for D versus B. This was expected due to the near-zero
meanandstandarddeviationestimatesofβ.Also,thepredictive
distributionsforfuturetrialsofthenewICDwereverysimilarto
those for existing ICDs (Figure 2). The between-trial variance,
τ2, was estimated as having a mean of 0.031(on the log RR
scale). The Monte Carlo standard errors of the mean estimates,
were as small as 0.003 for the D-B comparison.
DISCUSSION
We have presented a Bayesian, random-effects, MTC meta-
analysis incorporating pertinent external information. This can
be used for the evaluation of new versions of medical devices,
for which trial data is not yet available. It adapts an established
technique of plugging a functional relationship between a tar-
get parameter and an adjustment parameter into an evidence
synthesis model (1). Based on the current literature on bias
modeling (23;25), an intuitively simple additive parameter was
used to capture expected departures of the effectiveness of the
new device from the old one.
We illustrated this approach, obtaining mortality estimates
for a new ICD device based on a mixture of expert opinion and
empirical evidence on existing ICDs. This example was chosen
asthereisrelativelylargeexistingevidencebaseforICDs,while
further data collection on a new variant may be expensive and
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difﬁcult due to the invasive nature of the technology. In this ex-
ample, the incorporation of expert opinion on the new technol-
ogy made very little difference. However, the proposed method
could potentially change a technology adoption decision, de-
pending on how positive and strong the experts’ beliefs are.
Whether the suggested method should help to inform man-
ufacturers’ decisions about development, or payers’ decisions
about reimbursement, depends on the intrinsic reliability of
expert opinion—are they right in their expectations about the
worth of a new version of a device more often than they are
wrong? It also depends on the robustness of methods used to
elicit expert opinion and to combine it with prior evidence.
Even well-designed elicitation processes can be subject to
cognitive or behavioral bias, and there are further uncertainties
associated with the selection of experts and methods of syn-
thesizing elicited data. There is not currently a prescription for
how best to elicit and pool expert opinion. In our example, we
recruited experts from a relevant conference. These individuals
might not reﬂect the spectrum of beliefs of cardiac specialists,
which could explain the relatively small within- and between-
expertvariation.Theuseofindividualinterviews,ratherthanan
actualornominalgroupapproachmightalsohaveinﬂuencedthe
results; with feedback and/or a chance for discussion, opinions
might have evolved (19). The speciﬁc design and wording of
our questionnaire might also have had an impact. For example,
we informed participants that there is a ﬁxed 5-year mortality
rate of 35 percent with existing version of ICDs, which may
underestimate uncertainty over β.
The chosen effectiveness parameter in our analysis was
all-cause mortality. However, the dominant opinion of the in-
terviewed experts was that the change in the lead connector is
morelikelytobeassociatedwithothercomplicationrates,asthe
modiﬁed lead may be related to higher rates of lead dislodge-
mentandinsulationdefects.Ifothereffectivenessmeasureshad
been chosen, it is possible the experts might have anticipated
a “substantial departure from current ICD connector systems”
(10). This suggests that preliminary, qualitative discussion with
expertsisveryimportanttoidentifythekeyparametersofinter-
est. It would also be relatively straightforward to elicit a range
of outcomes, including resource use or cost estimates required
for an early assessment of cost-effectiveness. However, elicita-
tion of probability distributions is time-consuming, so care is
needed not to overburden respondents.
Validity of the meta-analysis model must also be consid-
ered. Various assumptions on the model structure could have
been made. An overarching assumption is that heterogeneity in
the data associated with the earlier versions of ICDs is less than
the difference between the new IS-4 device and the earlier ver-
sions. Although around 44 percent of the total variation in trial
estimates that is due to heterogeneity is considered reasonable
inthecurrentstudy,thereismuchvariationinthelevelsofdoses
of anti-arrhythmic drugs and other adjuvant therapies such as
theuseofbetablockersacrossstudies.Thereareseveralwaysto
address such heterogeneity problems (8). As in any systematic
review and meta-analysis, it is also important to consider the
potential for other forms of bias; such as publication bias.
Wealsonotethat,whereasBayesianincorporationofexpert
opinion can help consolidate existing opinion and data, these
methods cannot substitute for long term evaluation of rare ad-
verse events. Post-marketing follow-up studies are essential in
ensuring that new variants of a device do not impose additional
harms. Expert opinions on rare adverse events have limited use.
Because of the rarity of these events, not all experts will have
encountered them. Furthermore, the issue of when a difference
in a new variant of a device is sufﬁciently large to warrant pri-
mary randomized controlled trials is fundamental. In relation
to this, the proposed method has another potential use: if future
research generates evidence on the new variants, the estimates
obtained by this method can also serve as prior information in
the sequential use of Bayesian evidence synthesis.
CONCLUSIONS
Despite these caveats, the suggested method may play a use-
ful role in assisting decision makers to make early informed
judgments about evolving healthcare technologies. Before any
formalclinicalevidenceisgathered,quantiﬁedopinioncanpro-
vide some indication of expected beneﬁts from early adoption
and further evidence collection. This method provides a means
for formally including experts’ opinion into an evidence syn-
thesis model, which can be updated as more evidence emerges.
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APPENDIX 1: MATHEMATICAL REPRESENTATION OF THE MTC
MODEL WITH ADJUSTMENT FOR THE NEW TECHNOLOGY
Foreachtriali,theincludedtreatmentearliestinthealphabet(labeledwiththe
index b below) was taken as the baseline treatment (e.g., in trials comparing
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Aw i t hB ,b= A). The Bayesian MTC model, with adjustment for a new,
modiﬁed device, is shown in Eq. 1.
rk,i ∼ Binomial(pk,i,n k,i)
log(pk,i) =

µib b = A,B,C.if k = b
µib + δU
ikb if k alphabeticallyafterb
δU
ikb = min{δikb,−µib =−log(pb,i)}
δikb ∼ Normal(dkb + βi,τ2) ∼ Normal((dAk − dAb) + βi,τ2)
βi ∼ Normal

µβ,σ2
β

Priors : −µib ∼ Gamma(.001,.001),
dAk ∼ Normal(0,10000),wherek = B,D,
τ ∼ Uniform(0,2)
(Eq. 1)
where rk,i are the number of deaths out of the total number of patients at
risk nk,i for each treatment k in study i; pk,i is the probability of death in
study i under treatment k; µib is the logarithm of baseline mortality risk for
trial i. The parameter δikb represents the log relative risk (LRR) of treatment
k relative to baseline treatment b for study i. The nuisance parameter δU
ikb
is included to constrain the range of probabilities of an event below 1 (see
(40)). These trial-speciﬁc LRR are drawn from a common distribution, and
the pooled LRR, dbk, is deﬁned with respect to the reference treatment A (e.g.
dBC = dAC − dAB). The inclusion of β signiﬁes the mean mortality effect of
the conventional device estimated from observed data is deviated from the
effect of the new device, dkb by the magnitude of β.
Finally, a ﬂat Gamma prior was speciﬁed for the negative of µibto con-
strain the range of µib below 0, and Normal priors for the ‘basic parameters’
whose comparators are the reference treatment A. The between-study vari-
ance (heterogeneity parameter),τ2, was assigned a Uniform prior. The poten-
tial correlation between relative effectiveness parameters for trials involving
more than two arms were not considered in this study for simplicity.
Expert opinions form the basis of estimating µβand σβ. Although βis
represent the difference between two log relative risks, actual questions asked
expertstodirectlycomparetheproportionofpatientswhowoulddieunderthe
modiﬁed device therapy with that under the conventional device treatment.
This was justiﬁed by the relationshipE(δiCb) = dDb + E(βi) = dDb + µβ,
where both δ and d denote the log relative risks, but δ compares the baseline
treatment with treatment C while d does with treatment D. Taking away the
logarithm from the above relationship gives:
e
βi =
E

RRC
i

RRD ≈
PC/PControl
PD/PControl
=
PC
PD
P is a risk of death and RR a relative risk. The mortality risk under control
treatment,PControl,cancelsout,makingpossiblethedirectcomparisonbetween
treatments C and D, i.e.,PC and PD.
APPENDIX 2: FULL BUGS CODE FOR MTC MODEL WITH
ADJUSTMENT PARAMETER INCORPORATED
model{
#Model deﬁnedattreatmentarmlevel(Narm=25)
for(i in 1:Narm)
{
log(p[i])<-mu[s[i]]+delta.u[i] ∗ (1-equals(t[i],b[i]))
r[i]∼dbin(p[i],n[i])
rhat[i]<-p[i] ∗n[i]
dev[i] <-2 ∗(r[i]∗(log(r[i])-log(rhat[i])) +(n[i]-r[i])∗(log(n[i]-r[i])
-log(n[i]-rhat[i])))
delta.u[i] <-min(delta[i], -mu[s[i]])
delta[i]∼dnorm(md[i],prec)
md[i]<-d.study[i] +beta[s[i]]∗equals(t[i], 3)
#betato beincludedonly when thetreatmentisICD (trt=3)
d.study[i] <-d[t[i]]- d[b[i]]
}
#Information on distributionof beta
mu.beta<-0.001680164
prec.beta<-1/pow(0.006045638,2)
#Priorsandadjustmentatthe studylevel(Nstud=12)
for(j in 1:NStud)
{
mu[j] <-0- mu.minus[j]
mu.minus[j]∼dgamma(0.001,0.001)
beta[j]∼dnorm(mu.beta,prec.beta)
}
#Treatmentlevelprior(NTrt=3)
d[1]<-0
for (k in 2:NTrt)
{
d[k] ∼dnorm(0,0.0001)
}
#Predictivedistribution
d.pred[1]<-0
for (k in 2:NTrt)
{d.pred[k]∼dnorm(d[k],prec)}
#PairwiseLRR andRR: newICD
for (c in 1:2){
for (k in (c+1):3){
lrr[c,k] <-d[k]-d[c]
log(rr[c,k])<-lrr[c,k]
lrr.pred[c,k] <-d.pred[k]-d.pred[c]
log(rr.pred[c,k]) <-lrr.pred[c,k]
}
}
prec<-1/tau.sq
tau.sq<-t a u ∗tau
tau ∼dunif(0,2)
resdev<-sum(dev[]) #Residualdeviance
}
#Data
list(Narm=25,NStud=12,NTrt= 3)
s[] t[] r[] n[] b[]
1 1 244 847 1
1 2 240 845 1
1 3 182 829 1
2 1 58 342 1
2 3 62 332 1
3 1 40 229 1
3 3 28 229 1
4 1 97 490 1
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4 3 105 742 1
5 1 95 454 1
5 3 101 446 1
6 1 131 617 1
6 3 105 595 1
7 1 17 54 1
7 3 13 50 1
8 2 122 509 2
8 3 80 507 2
9 2 98 331 2
9 3 83 328 2
10 2 39 101 2
10 3 15 95 2
11 2 7 52 2
11 3 6 51 2
12 2 40 92 2
12 3 36 99 2
END
APPENDIX 3: SAMPLE QUESTIONNAIRE USED TO ASSIST VERBAL
INTERVIEWS
What is your opinion of the likely impact of the four-pole connector on
mortality?
According to the SCD-HeFT∗ and AVID∗∗ studies, on average around 35%
of ICD patients (both primary and secondary prevention) currently die within
5 years due to cardiac and non-cardiac causes.
Do you think it is likely that 5-year mortality would improve as a result of
using a four-pole connector, compared to the current connector system?
Yes No Don’tknow
Supposethat1,000patientsweretohaveanICDimplanted.Howmanydeaths,
on average, do you think might be averted/caused over a 5 year period if a
four-pole connector was used instead of a conventional ICD?
Minimum Your BestGuess Maximum
[number]more/ [number]more/ [number]more/
less(tick) deaths less(tick) deaths less(tick)deaths
Please try to represent your opinion on the scale below by distributing a total
of 100 points between the lines to reﬂect your subjective beliefs about each
range occurring.
|||| | | | ||||
−25 −20 −15 −10 −50+5 +10 +15 +20 +25
Numberof liveslostper1,000patients Numberof livessavedper1,000patients
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